Comparative Pharmacology
Head-to-head clinical analysis: AURYXIA versus RENAGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AURYXIA versus RENAGEL.
AURYXIA vs RENAGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AURYXIA (ferric citrate) is a phosphate binder that reduces serum phosphate by binding dietary phosphate in the gastrointestinal tract, forming insoluble ferric phosphate complexes that are excreted in the feces. The iron component also increases serum iron parameters and may improve iron stores.
Sevelamer is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, preventing its absorption and reducing serum phosphate levels.
Adult: 1 tablet (1700 mg ferric citrate) three times daily with meals, titrated every 2-4 weeks to achieve target serum phosphate levels. Maximum dose: 12 tablets per day.
Initial dose: 800-1600 mg orally three times daily with meals. Titrate by 1 tablet/capsule per meal based on serum phosphorus levels. Maintenance: typically 2-4 tablets/capsules per meal.
None Documented
None Documented
Not applicable; systemic absorption is minimal. AURYXIA is not absorbed and acts locally in the GI tract.
Not applicable (non-absorbable polymer; systemic absorption <0.01%).
Primarily fecal as unabsorbed drug (≥99%). Renal excretion is negligible (<1%).
Renal: 0%; Fecal: >99% (as intact drug, due to non-absorbable polymer). Biliary: negligible.
Category C
Category C
Phosphate Binder
Phosphate Binder